SPECTRUM PHARMACEUTICALS INC (SPPI) Stock Price, Quote, News and Overview
NASDAQ:SPPI - Nasdaq - US84763A1088 - Common Stock - Currency: USD
SPPI Quote, Performance and Key Statistics
1.03
0 (0%)
The current stock price of SPPI is 1.03 USD. In the past month the price increased by 7.29%. In the past year, price decreased by -2.83%.
SPPI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SPPI
Company Profile
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. The company is headquartered in Henderson, Nevada and currently employs 86 full-time employees. The firm is focused on acquiring, developing, and commercializing targeted oncology therapies. The firm's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
Company Info
SPECTRUM PHARMACEUTICALS INC
11500 S Eastern Ave Ste 240
Henderson NEVADA 89052 US
CEO: Joseph W. Turgeon
Employees: 86
Company Website: https://www.sppirx.com/
Phone: 17028356300.0
SPECTRUM PHARMACEUTICALS INC / SPPI FAQ
What is the stock price of SPECTRUM PHARMACEUTICALS INC today?
The current stock price of SPPI is 1.03 USD.
What is the ticker symbol for SPECTRUM PHARMACEUTICALS INC stock?
The exchange symbol of SPECTRUM PHARMACEUTICALS INC is SPPI and it is listed on the Nasdaq exchange.
On which exchange is SPPI stock listed?
SPPI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SPECTRUM PHARMACEUTICALS INC stock?
10 analysts have analysed SPPI and the average price target is 1.29 USD. This implies a price increase of 24.78% is expected in the next year compared to the current price of 1.03. Check the SPECTRUM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SPECTRUM PHARMACEUTICALS INC worth?
SPECTRUM PHARMACEUTICALS INC (SPPI) has a market capitalization of 211.40M USD. This makes SPPI a Micro Cap stock.
How many employees does SPECTRUM PHARMACEUTICALS INC have?
SPECTRUM PHARMACEUTICALS INC (SPPI) currently has 86 employees.
What are the support and resistance levels for SPECTRUM PHARMACEUTICALS INC (SPPI) stock?
SPECTRUM PHARMACEUTICALS INC (SPPI) has a support level at 1 and a resistance level at 1.03. Check the full technical report for a detailed analysis of SPPI support and resistance levels.
Is SPECTRUM PHARMACEUTICALS INC (SPPI) expected to grow?
The Revenue of SPECTRUM PHARMACEUTICALS INC (SPPI) is expected to grow by 722.64% in the next year. Check the estimates tab for more information on the SPPI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SPECTRUM PHARMACEUTICALS INC (SPPI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SPPI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SPPI, evaluating the profitability, health, valuation and growth aspects
- SPECTRUM PHARMACEUTICALS INC (SPPI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SPECTRUM PHARMACEUTICALS INC (SPPI) Sales and EPS estimates to see what analysts future expectations are.
- SPECTRUM PHARMACEUTICALS INC (SPPI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SPECTRUM PHARMACEUTICALS INC (SPPI) Insider and Institutional Ownership to learn about the owners and their transactions.
- SPECTRUM PHARMACEUTICALS INC (SPPI) Stock Chart to make your own analysis
- SPECTRUM PHARMACEUTICALS INC (SPPI) Latest news and press-releases to stay up to date.
Does SPECTRUM PHARMACEUTICALS INC (SPPI) stock pay dividends?
SPPI does not pay a dividend.
When does SPECTRUM PHARMACEUTICALS INC (SPPI) report earnings?
SPECTRUM PHARMACEUTICALS INC (SPPI) will report earnings on 2023-11-08, before the market open.
What is the Price/Earnings (PE) ratio of SPECTRUM PHARMACEUTICALS INC (SPPI)?
SPECTRUM PHARMACEUTICALS INC (SPPI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.36).
SPPI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SPPI. When comparing the yearly performance of all stocks, SPPI is a bad performer in the overall market: 61.3% of all stocks are doing better.
SPPI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SPPI. SPPI may be in some trouble as it scores bad on both profitability and health.
SPPI Financial Highlights
Over the last trailing twelve months SPPI reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 58.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 1.08 |
SPPI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to SPPI. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 88.67% and a revenue growth 722.64% for SPPI